Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Decreased atherosclerotic lesion formation in human serum paraoxonase transgenic mice.

Aaron Tward1, Yu-Rong Xia, Xu-Ping Wang

  • 1Department of Medicine, University of California, Los Angeles 90095-1679, USA.

Circulation
|July 24, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A liver-heart endocrine axis revealed by systems genetics and mediated by hepatocyte growth factor activator.

medRxiv : the preprint server for health sciences·2026
Same author

p21<sup>+</sup>TREM2<sup>+</sup> senescent macrophages fuel inflammaging and metabolic dysfunction-associated steatotic liver disease.

Nature aging·2026
Same author

Novel candidate genes for vestibular function identified through GWAS in the hybrid mouse diversity panel.

BMC genomics·2026
Same author

Genetic factors contributing to atherosclerosis.

Current opinion in cardiology·2026
Same author

Spatiotemporal profiling reveals distinct dynamics and checkpoint regulations of CAR-T and CAR-NKT cells against solid tumors.

Signal transduction and targeted therapy·2026
Same author

The liver regulates ectopic calcification in Abcc6-deficient models of pseudoxanthoma elasticum.

The Journal of clinical investigation·2026

Serum paraoxonase (PON1) protects against atherosclerosis. Increased PON1 levels in transgenic mice significantly reduced atherosclerotic lesions and LDL oxidation, suggesting its therapeutic potential for cardiovascular disease.

Area of Science:

  • Biochemistry
  • Cardiovascular Science
  • Genetics

Background:

  • Serum paraoxonase (PON1) is an HDL-associated enzyme that inhibits LDL oxidation.
  • Low PON1 activity is linked to atherosclerosis in human studies.
  • PON1 knockout mice exhibit increased susceptibility to lipoprotein oxidation and atherosclerosis.

Purpose of the Study:

  • To investigate the protective role of PON1 against atherosclerosis and lipid oxidation.
  • To determine if PON1 confers protection in a dose-dependent manner.

Main Methods:

  • Generation of human PON1 transgenic mice using bacterial artificial chromosome genomic clones.
  • Assessment of plasma PON1 and cholesterol levels.
  • Evaluation of atherosclerotic lesion development in dietary and apoE-null mouse models.

Related Experiment Videos

  • Testing the efficacy of HDL from transgenic mice in preventing LDL oxidation.

    • Main Results:

    • Transgenic mice exhibited 2- to 4-fold higher plasma PON1 levels without changes in plasma cholesterol.
    • Significant reduction in atherosclerotic lesions was observed in both dietary and apoE-null models.
    • HDL isolated from PON1 transgenic mice demonstrated enhanced protection against LDL oxidation.

    Conclusions:

    • PON1 effectively protects against atherosclerosis in a dose-dependent manner.
    • These findings highlight PON1 as a potential therapeutic target for cardiovascular disease treatment.